Skip to content
thestock.space

Jubilant Pharmova (JUBLPHARMA) had a P/E of 42.4× on 6 Nov 2026, above the industry P/E of 28.7×, and the shares are 19% below their 52-week high. Its ROCE of 6.3% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales grew 9.8% a year over 3 years. Its dividend yield is 0.5%, and debt is 0.51× equity. It is a small-cap company with a market cap of ₹14,884 Cr, ranked 30th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 20% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹946.00
Day high
₹954.40
Day low
₹934.10
Prev. close
₹947.05
Volume
58.2K

Health check

1 fair · 5 to check
  • ReturnsBehind

    −19.8% over a year, better than 0 of 7 peers.

  • Price tagPricier

    P/E 42.4 vs industry 28.7.

  • GrowthSlow

    Sales +9.8% a year over 3 years.

  • ProfitabilityWeak

    ROCE 6.3% vs peer median 17.9%.

  • Balance sheetFair

    Debt 0.51× equity, interest covered 4.0×, Piotroski 4 of 9.

  • Red flags2 to check

    Return on equity is low at 6.0%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹14,884 Cr, #30 of 154 in its industry by size.

Defensive

Beta 0.50 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹8,608 Cr · profit ₹352 Cr
Market cap
₹14,884 Cr
Small cap
P/E
42.4
Industry 28.7
Price to book
2.10
Peers 4.99
Dividend yield
0.53%
ROE
6.0%
Peers 14.7%
ROCE
6.3%
Peers 17.9%
Debt to equity
0.51
Debt ₹3,615 Cr
EPS (TTM)
₹22.17
Face value ₹1
OPM (TTM)
13.7%
Net margin 4.1%
Sales growth
+18.2%
Latest quarter vs a year ago
Profit growth
−45.1%
Latest quarter vs a year ago
Price to sales
1.73
EV/EBITDA 16.2

Strengths and risks

Strengths

  • Quarterly sales up 18.2% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Return on equity is low at 6.0%.
  • Quarterly profit down 45.1% on a year ago.

Derived automatically from reported figures. Not a recommendation.

About Jubilant Pharmova

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the…

Headquarters
Noida
Employees
5,657
Sector
Healthcare
ISIN
INE700A01033
Website
jubilantpharmova.com

Price range

52 weeks

₹786.05₹1,162.20

Today

₹934.10₹954.40
Avg volume (3M)
3.1 L
1-year return
minus 19.8%
From 52-week high
minus 19.2%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.87%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.30%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.81%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.59%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.93%minus 6.6%
JUBLPHARMAJubilant Pharmova939.60minus 0.79%14,88442.42.106.3%6.0%13.7%9.8%–0.53%minus 19.8%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.59%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrMar 25Jun 25Dec 25Mar 26Jun 26
1,9161,8792,1162,2722,221
–––+18.6%+18.2%
1,5701,5891,8271,9331,973
345290290339248
18.0%15.4%13.7%14.9%11.2%
11.811.920.423.719.9
52.74956.156.554.2
95.298.1121117127
−3.3–−39.7−13.7–
20615493.417686.4
26.6%33.6%40.3%32.2%34.7%
15410355.911956.5
–––minus 22.3%minus 45.1%
9.686.473.527.523.56

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+9.8%
ROE
6.0%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
6,2196,6457,1928,225
–+6.8%+8.2%+14.4%
5,4355,7406,0176,965
7849051,1751,260
12.6%13.6%16.3%15.3%
3172.536.952.2
169256221201
554382369440
−64.5−169358−56.1
27.8171981614
333.5%57.4%14.7%35.3%
−6177.1839399
––+988.7%minus 52.5%
-3.834.8652.8525.08

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
15.915.815.815.8
5,3835,4186,2397,077
3,6773,6642,7313,615
2,0812,4513,7714,815
11,15711,54912,75615,523
3,4633,8415,1796,922
8711,4062,7262,980
32.834.44267.7
1,0159631,0991,283
5,7745,3043,7114,271
11,15711,54912,75615,523

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
6619711,0721,227
−544−608488−1,260
−157−433−1,45394.9
−40.4−69.110761.7
−815−898−1,116−1,449
−15473.6−43.5−222
−80.1−79.8−79.6−79.5

Shareholding pattern

Source: NSE filings
47.7%
promoters
  • Promoters47.68%
  • Public51.78%
  • Employee trusts0.55%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202647.68%51.78%0.00
30 Jun 202647.68%51.77%0.00
31 Mar 202647.68%51.76%0.00
31 Dec 202547.68%51.75%0.00
30 Sep 202547.68%51.69%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you